#United States #San Francisco #Investor Rights #Securities Class Action #PROCEPT BioRobotics

Recent Developments in PROCEPT BioRobotics Class Action Lawsuit

Investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) are facing critical developments as a securities class action lawsuit has been initiated following concerns about the company’s financial practices. Hagens Berman Sobol Shapiro LLP is leading this effort, alerting investors who have experienced substantial financial losses from February 28, 2024, to February 25, 2026, to their right to participate in the class action before the looming deadline of September 22, 2026.

Background of the Lawsuit

The lawsuit arose from allegations that PROCEPT BioRobotics engaged in misleading sales practices. Specifically, the company reportedly misrepresented the performance of its single-use handpiece, an essential component used in their claim to fame, the Aquablation therapy for treating prostate enlargement. Despite promising growth and increased sales, it has come to light that the company was implementing an extensive bulk order discount scheme that led to inflated sales figures, misguiding investors about their true financial health.

This alleged misconduct included incentive programs that encouraged customers to make orders exceeding their actual needs. According to reports, this resulted in artificially high unit sales numbers in the short term, thereby creating a facade of sustained growth while setting the stage for inevitable inventory issues and subsequent financial discrepancies.

Key Insights from the Allegations

The complaint alleges that PROCEPT’s management knowingly withheld critical information from its investors. The emphasis on positive sales and the sidestepping of problematic inventory disclosures misled stakeholders about operational realities. This habit of highlighting sales boosts, particularly during quarterly earnings announcements, may have provided a false sense of security to investors.

Investors were only alerted to the ongoing issues through a series of partial disclosures, resulting in significant stock price declines. For instance, following not one, but two consecutive quarters of disappointing financial results in 2025, the market reacted sharply, causing the value of PROCEPT shares to plummet over 48% from a peak valuation reached earlier that year.

Timeline of Important Disclosures

• - August 2025: PROCEPT’s financial results reported significant underperformance in handpiece sales, which sharply missed estimates.
• - November 2025: Annual sales guidance was revised downwards as management acknowledged concerns regarding inventory management—realizing that customers had been left with excessive inventories.
• - February 25, 2026: The company revealed alarming numbers showing that handpiece sales consistently exceeded surgical procedures, leading to a buildup of over 10,000 excess units in inventory, further validating investor fears and concerns.

Call for Action

As these events unfolded, Hagens Berman has advocated for investors who have incurred losses to step forward. The firm urges anyone who invested in PROCEPT during the class period to consider joining the lawsuit. They welcome additional information from individuals who can assist the ongoing investigation.

Hagens Berman, known for its commitment to corporate accountability, underscores the importance of transparency and adherence to legal standards in corporate communications. With over $2.9 billion recovered for harmed investors, the firm seeks to hold PROCEPT accountable for any significant deviations from ethical practices.

If you are an investor with substantial losses, the time to act is now. For further details regarding your situation or if you have insights aiding the investigation, consider contacting Hagens Berman. You may also want to explore the SEC Whistleblower Program, which allows individuals with insider knowledge to possibly gain substantial rewards for aiding investigations into corporate misconduct.

Conclusion

As the September 22, 2026, deadline looms, affected shareholders should closely monitor developments in the PROCEPT BioRobotics lawsuit. Legal recourse is crucial for those who stand to recover losses stemming from corporate misdeeds. Stay informed and ready to act as this story continues to develop.